Related Experiment Video
Updated: Jun 19, 2025

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography
Published on: April 4, 2012
Non-Hereditary Obesity Type Networks and New Drug Targets: An In Silico Approach
Styliani A Geronikolou1,2, Athanasia Pavlopoulou3,4, Merve Uça Apaydin3,4
1Clinical, Translational Research and Experimental Surgery Centre, Biomedical Research Foundation of the Academy of Athens, 4, Soranou Ephessiou Str., 11527 Athens, Greece.
Abstract:
Obesity, a chronic, preventable disease, has significant comorbidities that are associated with a great human and financial cost for society. The aim of the present work is to reconstruct the interactomes of non-hereditary obesity to highlight recent advances of its pathogenesis, and discover potential therapeutic targets. Obesity and biological-clock-related genes and/or gene products were extracted from the biomedical literature databases PubMed, GeneCards and OMIM. Their interactions were investigated using STRING v11.0 (a database of known and predicted physical and indirect associations among genes/proteins), and a high confidence interaction score of >0.7 was set. We also applied virtual screening to discover natural compounds targeting obesity- and circadian-clock-associated proteins. Two updated and comprehensive interactomes, the (a) stress- and (b) inflammation-induced obesidomes involving 85 and 93 gene/gene products of known and/or predicted interactions with an average node degree of 9.41 and 10.8, respectively, were produced. Moreover, 15 of these were common between the two non-hereditary entities, namely, ADIPOQ, ADRB2/3, CCK, CRH, CXCL8, FOS, GCG, GNRH1, IGF1, INS, LEP, MC4R, NPY and POMC, while phelligridin E, a natural product, may function as a potent FOX1-DBD interaction blocker. Molecular networks may contribute to the understanding of the integrated regulation of energy balance/obesity pathogenesis and may associate chronopharmacology schemes with natural products.
Insights
This study maps gene networks in non-hereditary obesity, revealing stress and inflammation pathways. It identifies potential therapeutic targets and natural compounds for obesity treatment.
Area of Science:
- Genetics and Systems Biology
- Metabolic Disorders
- Chronobiology
Background:
- Obesity is a chronic, preventable disease with high societal costs due to comorbidities.
- Understanding the pathogenesis of non-hereditary obesity is crucial for identifying therapeutic targets.
- Biological clock genes play a role in energy balance and metabolic regulation.
Purpose of the Study:
- To reconstruct interactomes of non-hereditary obesity to elucidate pathogenesis.
- To identify potential therapeutic targets for obesity.
- To discover natural compounds targeting obesity and circadian clock-associated proteins.
Main Methods:
- Extracted obesity and biological-clock-related genes from PubMed, GeneCards, and OMIM.
- Investigated gene/protein interactions using STRING v11.0 with a high confidence score (>0.7).
- Applied virtual screening to identify natural compounds targeting relevant proteins.
Main Results:
- Developed two interactomes: stress-induced (85 genes) and inflammation-induced (93 genes) obesidomes.
- Identified 15 common genes between the two interactomes, including key metabolic and hormonal regulators (e.g., LEP, INS, MC4R).
- Phelligridin E identified as a potential FOX1-DBD interaction blocker.
Conclusions:
- Molecular networks provide insights into the integrated regulation of energy balance and obesity pathogenesis.
- Findings may link chronopharmacology with natural products for novel obesity treatments.
- Identified interactomes and compounds offer potential avenues for therapeutic intervention.
More Related Videos
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Protein-protein Interfaces
Drug Discovery: Overview
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Obesity

